Ascensia completes initial launch of Eversense E3 in Europe
By HME News Staff
Updated 9:35 AM CDT, Wed October 12, 2022
BASEL, Switzerland – Ascensia Diabetes Care has successfully completed the initial European launch of the next-generation Eversense E3 CGM System. The benefits of this fully-implantable, long-term CGM system are now available to people with diabetes in all launch markets across Europe in Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands and Andorra. “We are proud to have successfully brought the Eversense E3 to Europe, where we believe it can make a big difference in the lives of people with diabetes,” said Torstein Myhre, region head of Europe at Ascensia Diabetes Care. “The Eversense E3 CGM System makes managing diabetes easier, offering unparalleled convenience and flexibility alongside exceptional accuracy. With a six-month sensor lifespan, the system frees patients from frequent sensor insertions, and its other features have been specifically designed to address improvements desired by the diabetes community.” The Eversense E3, was approved earlier this year for use up to six months.
Comments